ChronoScale Corp. (NASDAQ: CHRN) said an expanded agreement with an existing AI infrastructure customer and a new customer deal, combined with current contracts and its deployment schedule, provide for a $1 billion annualized revenue run rate by the third quarter of calendar 2027. Shares rose 3% in after-hours trading Thursday. The company cautioned that achieving the target and its timing depend on timely infrastructure deployment, access to power and equipment, and financing on acceptable terms. ChronoScale also completed the sale of its Ekso Bionics business to Wandercraft, allowing it to focus operations and capital allocation on accelerated computing and AI infrastructure. Wandercraft is combining Ekso’s products and clinical network with its own robotic-mobility business, including Atalante X, EksoNR, Eve and Indego Personal, which serve rehabilitation and personal-mobility needs.